© 2007 European Society of Cardiology
Mutational screening of phospholamban gene in hypertrophic and idiopathic dilated cardiomyopathy and functional study of the PLN –42 C>G mutation
Hospital Universitario Juan Canalejo Spain
* Corresponding author. Servicio de Cardiologia, Complejo Hospitalario Universitario Juan Canalejo, As Xubias 84, A Coruna 15006, Spain. E-mail address: lorenzo_monserrat{at}canalejo.org
 |
Abstract |
|---|
Background: Phospholamban is an endogenous sarcoplasmic reticulum calcium ATPase inhibitor with a regulatory effect on cardiac contraction/relaxation coupling. Mutations in the phospholamban gene (PLN) have been associated with primary cardiomyopathies.
Aims: To screen for PLN mutations in our population of patients with primary cardiomyopathies and to perform functional analysis of the mutations identified.
Methods: We performed SSCP mutational screening and DNA sequencing of the PLN gene in 186 patients with either hypertrophic or dilated cardiomyopathy. To study promoter strength we constructed reporter plasmids containing the luciferase gene and performed transient transfection analysis in C6 and C2C12 cell lines.
Results: The PLN –42 C>G mutation was found in one patient with late onset familial apical hypertrophic cardiomyopathy. This mutation decreased phospholamban promoter activity by 43% and 47%, in C6 and C2C12 cell lines respectively. One son had mild apical hypertrophic cardiomyopathy and carried the mutation, another son with normal ECG and echocardiogram also had the mutation.
Conclusion: The PLN –42 C>G mutation is associated with a benign form of apical hypertrophic cardiomyopathy in this family, though the presence of a healthy adult carrier suggests that other genetic and environmental factors could be involved. Otherwise, mutations in the PLN gene are not a frequent cause of cardiomyopathies in our population.
Key Words: Phospholamban • Mutation • Promoter region • Hypertrophic cardiomyopathy
Received July 28, 2005; Revised February 14, 2006; Accepted April 11, 2006